TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29880162
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 cc saline infusion)
Study: 28654721
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of resin infiltration and bleaching
Study: 18465244
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. (RAC group, n = 30)
Study: 18465244
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus moxifloxacine 400 mg o.d. and amoxicillin 1,000 mg b.d. (RAM group, n = 30)
Study: 18465244
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus clarithromycin 500 mg b.d. (EAC group, n = 30)
Study: 10848858
Drug: Blue-hub needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue-hub needle (23 G) with local anaesthetic
Study: 10848858
Drug: Green-hub needle
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Green-hub needle (21 G) with local anaesthetic
Study: 22540912
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (1000 mg twice daily)
Study: 22540912
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus rosiglitazone (4 mg twice a day)
Study: 19709100
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E ointment 10% (G(10%))
Study: 19709100
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E ointment 15% (G(15%))
Study: 19709100
Drug: Vehicle (G(Veh))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (G(Veh))
Study: 2643934
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (2 micrograms/kg)
Study: 3881263
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 1,200 mg/day (Trental 400 t.d.s.)
Study: 3881263
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid and dipyridamole (ASAD, 1,050 mg + 150 mg/day)
Study: 30531477
Drug: PF-06372865 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06372865 2.5 mg twice daily
Study: 30531477
Drug: PF-06372865 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06372865 7.5 mg twice daily
Study: 28270181
Drug: Weekly paclitaxel-epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly paclitaxel-epirubicin (PE) regimen
Study: 28270181
Drug: Tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide (FEC) regimen
Study: 19730966
Drug: Promethazine 6.25
Normalized name: DM 15/PROMETHAZINE 6.25MG/5ML SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 6.25 mg iv
Study: 9591489
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) gonadotropins
Study: 9591489
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) gonadotropins
Study: 3348141
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of sustained-release isosorbide dinitrate (ISDN)
Study: 3348141
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of sustained-release nifedipine
Study: 30017873
Drug: Standardized dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized dry ivy leaf extract syrup along with regular nasal irrigation for five days after nasal packing removal
Study: 28223381
Drug: Gepotidacin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 1,000 mg
Study: 28223381
Drug: Gepotidacin 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 1,800 mg
Study: 24316325
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) at intervention sites
Study: 17631801
Drug: High-dose Dinggui
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Dinggui Oil (DGO-H, 1.2 g, 3 times daily)
Study: 14996420
Drug: Paternal lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paternal lymphocyte (PL) immunotherapy
Study: 14996420
Drug: Autologous lymphocyte
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous lymphocyte (AL) immunotherapy
Study: 14996420
Drug: Third party
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third party lymphocyte (TPL) immunotherapy
Study: 9410372
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Crinone) 90 mg per day
Study: 9410372
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone (Utrogestan) 300 mg per day
Study: 9410372
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone (Utrogestan)
Study: 6785626
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation with lysozyme, papain and bacitracin
Study: 31557351
Drug: T1D Exchange
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T1D Exchange Registry (injection users)
Study: 31557351
Drug: DPV Registry
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPV Registry (injection users)
Study: 28049170
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (500 µg twice daily) for 6 months
Study: 25863853
Drug: Glaucoma group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glaucoma group (31 patients using at least 1 topical IOP-lowering medication)
Study: 25863853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30 patients with no diagnosis of glaucoma or history of topical therapy usage)
Study: 20354183
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily
Study: 12611785
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy in addition to antidepressants and clinical management
Study: 7983993
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.5 mg/kg infused in 5% dextrose on alternate days for 14 doses)
Study: 7983993
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (20 mg/kg in two divided doses daily for 40 days)
Study: 26405263
Drug: UPA 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPA 30 mg followed by placebo matching DSG for 20 days
Study: 9099449
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Lamisil (terbinafine) once daily for 15 days under fed condition
Study: 31455425
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous (IV) zoledronic acid (ZA) in premenopausal women.
Study: 27099272
Drug: 300 min/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 min/wk of aerobic exercise (high dose)
Study: 21237568
Drug: S(+)‐ketamine (40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (40mg per 70kg) infusion
Study: 16441988
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (incision-curettage)
Study: 9085319
Drug: Pharmacist recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist recommendations to discontinue intravenous antibiotic therapy
Study: 2932213
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose medroxyprogesterone acetate (HD-MPA)
Study: 29474851
Drug: Greater dose
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater dose of PA in control schools
Study: 18813048
Drug: High-pressure injection
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-pressure injection (> 20 psi)
Study: 18813048
Drug: Low-pressure injection
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-pressure injection (< 15 psi)
Study: 11804979
Drug: Lytic monotherapy
Normalized name: Fytic acid
DrugBank: Phytic acid (DB14981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lytic monotherapy
Study: 10029609
Drug: Mesalamine tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine tablets, 4 g
Study: 22956052
Drug: Statin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin group (rosuvastatin 10 mg per day for 6 months)
Study: 17261626
Drug: Brecanavir (BCV)
Normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brecanavir (BCV) 50 to 600 mg with 100 mg ritonavir (RTV) every 12 hours or every 24 hours for 15 days
Study: 17261626
Drug: Brecanavir (BCV)
Normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brecanavir (BCV) 800 mg every 12 hours for 15 days
Study: 17261626
Drug: Brecanavir (BCV)
Normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brecanavir (BCV) with RTV 100 mg
Study: 15578510
Drug: Peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2a 180 mug/wk plus ribavirin 800 mg/day for 24 weeks
Study: 23299384
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 olive oil capsules per day for 6 months)
Study: 10674604
Drug: Quadruple anti-helicobacter
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple anti-helicobacter therapy
Study: 9058216
Drug: Methylprednisolone (MPS),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (MPS), 1 g IV before CPB
Study: 9058216
Drug: Aprotinin-full-dose protocol
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin-full-dose protocol
Study: 2946016
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effect (all groups)
Study: 25017182
Drug: Olmesartan 40‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40‐mg tablet
Study: 25017182
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of rosuvastatin 20‐mg tablet and olmesartan 40‐mg tablet
Study: 19875337
Drug: Both concurrent
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both concurrent and maintenance chemotherapy (SIM+SUB; n=154)
Study: 19875337
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with chemotherapy (SIM alone; n=118)
Study: 14671423
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment followed by balloon treatment
Study: 6225808
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of aztreonam
Study: 6232015
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of spectinomycin
Study: 11242379
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment
Study: 26555827
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment and Observation (crossover patients)
Study: 26555827
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment and Observation (patients with Cobb angles ≥ 40 degrees)
Study: 24783988
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with lopinavir 400 mg and ritonavir 100 mg plus lamivudine 150 mg, both twice daily
Study: 24783988
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with lopinavir 400 mg and ritonavir 100 mg twice daily plus lamivudine or emtricitabine and another NRTI
Study: 17556901
Drug: Omeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (10 or 20 mg)
Study: 15043959
Drug: Nicotinamide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (1.2 g/m2)
Study: 12093324
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 150 mg/day)
Study: 10184835
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 to 60 mg/day)
Study: 2523321
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg/day (increased to 800 mg/day if amenorrhea not achieved)
Study: 31892920
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GSC and NRT
Study: 26256429
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER 40 mg daily
Study: 26256429
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER 80 mg daily
Study: 26256429
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER 120 mg daily
Study: 26256429
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER (25-100 mg single dose)
Study: 26256429
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER (40, 80, 120 mg daily for 8 weeks)
Study: 19998046
Drug: 1% sucralfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sucralfate lotion
Study: 2764127
Drug: Naftidrofuryl, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl, 600 mg
Study: 1097036
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal diet without fibre supplements)
Study: 19663196
Drug: omeprasol 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprasol 20 mg twice a day
Study: 19663196
Drug: omeprasol 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprasol 20 mg twice a day + BTD 240 mg twice a day
Study: 10024613
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (7.8 mg daily)
Study: 7675298
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of methylcobalamin (MB12)
Study: 7675298
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline injections (placebo trial)
Study: 2254759
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of recombinant human granulocyte-macrophage colony-stimulating factor
Study: 28188670
Drug: PPV/CPA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV/CPA (100 mg/day for 7 days before vaccination)
Study: 25995280
Drug: Food, Activity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food, Activity, and Breastfeeding intervention (FAB) and Combination intervention (Combo)
Study: 10052663
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg x kg(‐1))
Study: 26580866
Drug: Fractional ablative
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional ablative Er:YAG 2940-nm laser (FELR) with topical anti-aging and anti-pigment agents followed by ultrasound treatment
Study: 26580866
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment following FELR and topical agents
Study: 26580866
Drug: FELR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FELR and topical agents alone
Study: 20502135
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy
Study: 17184146
Drug: Fenofibrate treatment
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate treatment for three months
Study: 9135178
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia with bupivacaine 0.5% followed by bupivacaine 0.375% infusion
Study: 12665489
Drug: Statin pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin pretreatment in patients with hsCRP > or =1.11 mg/dL
Study: 10388979
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (2.4 pmol.kg‐1.min‐1)
Study: 24170152
Drug: Pulse irrigation
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse irrigation with 2 L normal saline (<15 psi)
Study: 24170152
Drug: Standard irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard irrigation with 2 L normal saline poured into the wound
Study: 22451437
Drug: WHEY (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHEY (25 g of whey protein)
Study: 20050300
Drug: Electroacupuncture applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electroacupuncture applied to acupuncture points PC6 and HT7 for 20 minutes twice a week for 8 weeks
Study: 11286433
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pergolide
Study: 11286433
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pergolide
Study: 2896359
Drug: Zuclopenthixol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuclopenthixol (4 mg daily, increased if necessary over 4 weeks)
Study: 30928088
Drug: Concurrent control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent control group (Blacks 83.1% vs. Whites 90.1%, p < 0.001).
Study: 30928088
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group compared to concurrent control for Blacks.
Study: 26738450
Drug: Topical DLX105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DLX105 (0.5% hydrogel formulation)
Study: 25074252
Drug: Aspirin reload
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin reload (325 mg orally)
Study: 22815989
Drug: Polypill (amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg, simvastatin 40 mg)
Study: 19717646
Drug: Ketoprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (300 mg/day for 5 days)
Study: 17300594
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg twice daily (b.i.d.)
Study: 15144392
Drug: 20% ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ALA preparation in Eucerin cream applied under an occlusive dressing followed by irradiation with 75 J/cm² of broad-band red light.
Study: 11176160
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) therapy
Study: 8567093
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 200 mg/week
Study: 8567093
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline measurements before injections)
Study: 19300425
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 x 7 g/day)
Study: 1933601
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 3 years or 4 years
Study: 1933601
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 3 years
Study: 1933601
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 2 years
Study: 319936
Drug: Fenfluramine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine, 120 mg/day for 10 or more days
Study: 28426239
Drug: Usual insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual insulin pump + continuous glucose monitor (CGM) care at home
Study: 25354554
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between chemotherapy and genotype
Study: 23821768
Drug: Risperidone or
Normalized name: risperidone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone or olanzapine dose reduction (50% in 4 weeks, maintained thereafter)
Study: 25099201
Drug: Maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance group (dose kept constant)
Study: 1514532
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride administration